Advertisement
U.S. markets open in 7 hours 2 minutes

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
0.5868-0.0179 (-2.96%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
MACD

MACD

Previous Close0.6047
Open0.5900
Bid0.4410 x 100
Ask0.6390 x 100
Day's Range0.5713 - 0.6400
52 Week Range0.5580 - 2.4200
Volume17,618
Avg. Volume63,359
Market Cap4.975M
Beta (5Y Monthly)0.20
PE Ratio (TTM)N/A
EPS (TTM)-2.3300
Earnings DateMay 13, 2024 - May 17, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EVOK

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Evoke Pharma, Inc.
    ANIP: Raising target price to $73.00ANI PHARMACEUTICALS INC has an Investment Rating of HOLD; a target price of $73.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer

    SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D’Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer’s departure for personal reasons. Mr. D’Onofrio currently serves as President and Chief Operating Officer. “Worki

  • Simply Wall St.

    Evoke Pharma, Inc. (NASDAQ:EVOK): Are Analysts Optimistic?

    We feel now is a pretty good time to analyse Evoke Pharma, Inc.'s ( NASDAQ:EVOK ) business as it appears the company...

  • Insider Monkey

    Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript

    Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2023 Earnings Call Transcript March 14, 2024 Evoke Pharma, Inc. misses on earnings expectations. Reported EPS is $-0.59 EPS, expectations were $-0.5. Evoke Pharma, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, […]